Safety and Tolerability of PCSK9 Inhibitors: Current Insights

Autor: Kosmas CE, Skavdis A, Sourlas A, Papakonstantinou EJ, Peña Genao E, Echavarria Uceta R, Guzman E

Publikováno v: Clinical Pharmacology: Advances and Applications, Vol Volume 12, Pp 191-202 (2020)

Constantine E Kosmas,1 Andreas Skavdis,2 Andreas Sourlas,3 Evangelia J Papakonstantinou,4 Edilberto Peña Genao,5 Rogers Echavarria Uceta,5 Eliscer Guzman1 1Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, USA; 2S

Externí odkaz: https://doaj.org/article/817a135acf6143918c3328e778e3ad40

New and emerging lipid-modifying drugs to lower LDL cholesterol.

Autor: Kosmas CE; Department of Medicine, Division of Cardiology, Montefiore Medical Center, Bronx, NY, USA.; Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USA., Pantou D; School of Medicine, University of Nicosia, Nicosia, Cyprus., Sourlas A; School of Medicine, University of Crete, Heraklion, Greece., Papakonstantinou EJ; General Directorate of Public Health and Social Welfare, Attica Region, Athens, Greece., Echavarria Uceta R; Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USA., Guzman E; Department of Medicine, Division of Cardiology, Montefiore Medical Center, Bronx, NY, USA.; Cardiology Clinic, Cardiology Unlimited, PC, New York, NY, USA.

Publikováno v: Drugs in context [Drugs Context] 2021 Nov 01; Vol. 10. Date of Electronic Publication: 2021 Nov 01 (Print Publication: 2021).